Free Newsletter

FEATURES >> 15 Top Blockbuster Contenders | 10 Promising Therapeutic Vaccines

Related Topics >> FDA | AstraZeneca | MedImmune | motavizumab

MedImmune's new RSV drug faces delay

December 1, 2008 — 11:27am ET | By John Carroll

Related Stories

Tools

The FDA is asking for more information related to motavizumab, a treatment that is intended to fight RSV. MedImmune declined to say exactly what the FDA is looking for, but said that it plans to refile for approval in the first half of 2009. Release l Report

SHARE
WITH:

More stories about FDA AstraZeneca MedImmune motavizumab